<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615145</url>
  </required_header>
  <id_info>
    <org_study_id>P15-398</org_study_id>
    <nct_id>NCT02615145</nct_id>
  </id_info>
  <brief_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)</brief_title>
  <acronym>LIFE-C</acronym>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without
      dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC)
      has been shown to be safe and effective in randomized controlled clinical trials with strict
      inclusion and exclusion criteria under well controlled conditions.

      This observational study is the first effectiveness research examining the ABBVIE REGIMEN ±
      RBV, used according to local label, under real world conditions in Germany in a clinical
      practice patient population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2015</start_date>
  <completion_date type="Actual">March 26, 2018</completion_date>
  <primary_completion_date type="Actual">March 26, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug (treatment period was 12 or 24 weeks)</time_frame>
    <description>SVR12 is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (&lt; 50 IU/mL) 12 weeks after the last actual dose of the ABBVIE REGIMEN.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virological Response at End of Treatment (EoTR)</measure>
    <time_frame>EoT, (treatment period was 12 weeks or 24 weeks)</time_frame>
    <description>Virological response is defined as HCV RNA &lt; 50 IU/mL. End of Treatment (EoT) is defined as the last intake of ABBVIE REGIMEN or RBV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With On-Treatment Virological Failure or Relapse</measure>
    <time_frame>Up to post-treatment Week 12 (treatment period was 12 or 24 weeks)</time_frame>
    <description>The number of participants meeting the following SVR12 non-response categories:
On-treatment virological failure (breakthrough) defined &gt;= 1 documented HCV RNA &lt; 50 IU/mL followed by HCV RNA &gt;= 50 IU/mL during treatment or failure to suppress (each measured on-treatment HCV RNA value &gt;= 50 IU/mL)
Relapse defined as HCV RNA &lt; 50 IU/mL at EoT followed by HCV RNA &gt;= 50 IU/mL post-treatment in participants who completed treatment (&lt;= 7 days shortened).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rapid Virological Response at Week 4 (RVR4)</measure>
    <time_frame>Week 4</time_frame>
    <description>RVR4 is defined as participants with HCV RNA &lt; 50 IU/mL at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virological Response 24 Weeks After EoT (SVR24)</measure>
    <time_frame>24 Weeks After EoT (treatment period was 12 or 24 weeks)</time_frame>
    <description>SVR24 is defined as HCV RNA &lt; 50 IU/mL 24 Weeks After EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virological Response 48 Weeks After EoT (SVR48)</measure>
    <time_frame>48 Weeks After EoT (treatment period was 12 or 24 weeks)</time_frame>
    <description>SVR48 is defined as participants with HCV RNA &lt; 50 IU/mL 48 weeks after EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PRISM Over Time</measure>
    <time_frame>Baseline, 12 and 48 weeks after EoT (treatment period was 12 or 24 weeks)</time_frame>
    <description>PRISM is a visual quantitative method to assess the perceived burden of suffering due to illness. The distance between the center of the &quot;self&quot; (yellow disk) and the illness disk (red disk) is called &quot;self-illness separation&quot; (SIS) and is measured in cm (range is 0 - 27). The smaller the distance, the higher the burden of suffering.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 1 Comorbidity and/or Co-Infection</measure>
    <time_frame>up to post-treatment Week 48 (treatment period was 12 or 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Taking ≥ 1 Co-Medication</measure>
    <time_frame>up to post-treatment Week 48 (treatment period was 12 or 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Duration of of ABBVIE REGIMEN and RBV Taken</measure>
    <time_frame>Up to Week 12 or Week 24</time_frame>
    <description>Documented by participant interview and/or participant diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Planned Duration of ABBVIE REGIMEN and RBV Taken</measure>
    <time_frame>Up to Week 12 or Week 24</time_frame>
    <description>Planned duration of treatment was 12 or 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FACIT-F Scale Over Time</measure>
    <time_frame>Baseline, EoT (treatment period was 12 or 24 weeks), 12 and 48 weeks after EoT</time_frame>
    <description>The FACIT-F Scale is a 13-item questionnaire that assesses self-reported fatigue during the past 7 days and its impact upon daily activities and function. Scores range from 0 - 100, with higher scores indicating a lesser degree of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to EoT in PAM-13 Questionnaire</measure>
    <time_frame>Baseline, EoT (treatment period was 12 or 24 weeks)</time_frame>
    <description>The PAM-13 item scale is a measure used to assess the patient knowledge, skill, and confidence for self-management. Scores range from 0 to 100. Higher scores indicate a higher level of knowledge, skill and confidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time in WPAI: Total Work Productivity Impairment</measure>
    <time_frame>Baseline, EoT (treatment period was 12 or 24 weeks),12 and 24 weeks after EoT</time_frame>
    <description>The WPAI Hepatitis C V2.0 is an HCV specific questionnaire used to measure work absenteeism, work presenteeism, and daily activity impairment. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity.
Total work productivity impairment indicates the percentage of overall work impairment due to health problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time in WPAI: Total Activity Impairment</measure>
    <time_frame>Baseline, EoT (treatment period was 12 or 24 weeks),12 and 24 weeks after EoT</time_frame>
    <description>The WPAI Hepatitis C V2.0 is an HCV specific questionnaire used to measure work absenteeism, work presenteeism, and daily activity impairment. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity.
Total activity impairment indicates the percentage of general (non-work) activity impairment due to health problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and/or Pregnancies</measure>
    <time_frame>up to 30 days post treatment (treatment period was 12 weeks or 24 weeks)</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence. If an AE meets any of the following criteria, it is considered serious: results in death, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in significant disability/incapacity, or is an important medical event. TEAEs are defined as any reported event that begins or worsens in severity after initiation of study drug through 30 days post-study drug dosing.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">472</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Genotype 1a (G1a) Participants</arm_group_label>
    <description>Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC) genotype 1a (G1a, includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) + ribavirin (RBV) according to standard of care and in line with the current local label.
The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1b (G1b) Participants</arm_group_label>
    <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/Genotype 4 [G4]), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.
The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4 (G4) Participants</arm_group_label>
    <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.
The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Hepatitis C (CHC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naïve or -experienced patients with confirmed CHC, genotype 1 or 4,
             receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV according
             to standard of care and in line with local label.

          -  If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line with
             the current local label (with special attention to contraception requirements and
             contraindication during pregnancy)

          -  Patients must voluntarily sign and date a patient authorization to use and/or disclose
             his/her pseudonymized health data prior to inclusion into the study

          -  Patient must not be participating or intending to participate in a concurrent
             interventional therapeutic trial

        Exclusion Criteria:

        • Adolescents; people not treated according to label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <results_first_submitted>March 20, 2019</results_first_submitted>
  <results_first_submitted_qc>September 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 7, 2019</results_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Dasabuvir</keyword>
  <keyword>Ombitasvir+Paritaprevir+Ritonavir</keyword>
  <keyword>Observational Study</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Work-ability</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02615145/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02615145/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this prospective, multi-center observational study, adult patients chronic hepatitis C (CHC) virus receiving the interferon-free ABBVIE REGIMEN (paritaprevir/r - ombitasvir with or without dasabuvir) with or without ribavirin (RBV) were offered the opportunity to participate in this study during a routine clinical visit at participating sites.</recruitment_details>
      <pre_assignment_details>Per protocol, the Enrolled Population is used to present Participant Flow. Enrolled Population analysis groups are defined according to the participant’s HCV genotype/subtype, regardless of ABBVIE Regimen prescribed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Genotype 1a Participants</title>
          <description>Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC) genotype 1a (G1a, includes all GT1- participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) + ribavirin (RBV) according to standard of care and in line with the current local label.</description>
        </group>
        <group group_id="P2">
          <title>Genotype 1b Participants</title>
          <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/G4), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.</description>
        </group>
        <group group_id="P3">
          <title>Genotype 4 Participants</title>
          <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
        </group>
        <group group_id="P4">
          <title>Missing</title>
          <description>Treatment-naïve or -experienced participants with confirmed CHC but no genotype information.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="278"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2 DAA + Ribavirin (RBV)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3DAA</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="261"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3DAA + RBV</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="263"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did Not Start Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Return</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population: all enrolled participants who received ≥1 dose of ABBVIE REGIMEN, grouped according to treatment regimen (actual treatment received). This presentation was necessary for baseline characteristics since some study-specific measures for which Baseline data are required were analyzed only according to actual treatment received.</population>
      <group_list>
        <group group_id="B1">
          <title>2 DAA+RBV</title>
          <description>Two direct-acting antivirals (2DAA): paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV</description>
        </group>
        <group group_id="B2">
          <title>3DAA</title>
          <description>Three direct-acting antivirals (3DAA): paritaprevir/ritonavir - ombitasvir + dasabuvir (ABBVIE REGIMEN)</description>
        </group>
        <group group_id="B3">
          <title>3DAA+RBV</title>
          <description>3DAA: paritaprevir/ritonavir - ombitasvir + dasabuvir (ABBVIE REGIMEN) plus RBV</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="266"/>
            <count group_id="B3" value="159"/>
            <count group_id="B4" value="470"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="266"/>
                    <count group_id="B3" value="159"/>
                    <count group_id="B4" value="470"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="11.5"/>
                    <measurement group_id="B2" value="55" spread="13.6"/>
                    <measurement group_id="B3" value="49" spread="11.9"/>
                    <measurement group_id="B4" value="52" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="266"/>
                    <count group_id="B3" value="159"/>
                    <count group_id="B4" value="470"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="266"/>
                    <count group_id="B3" value="159"/>
                    <count group_id="B4" value="470"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="266"/>
                    <count group_id="B3" value="159"/>
                    <count group_id="B4" value="470"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Oriental</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="266"/>
                    <count group_id="B3" value="159"/>
                    <count group_id="B4" value="470"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, Not Specified</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="266"/>
                    <count group_id="B3" value="159"/>
                    <count group_id="B4" value="470"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pictorial Representation of Illness and Self-Measure (PRISM) Tool</title>
          <description>PRISM is a visual quantitative method to assess the perceived burden of suffering due to illness. The distance between the center of the “self” (yellow disk) and the illness disk (red disk) is called “self-illness separation” (SIS) and is measured in cm (range is 0 - 27). The smaller the distance, the higher the burden of suffering.</description>
          <population>participants with a Baseline assessment</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="158"/>
                    <count group_id="B4" value="464"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.1" spread="9.16"/>
                    <measurement group_id="B2" value="12.3" spread="8.78"/>
                    <measurement group_id="B3" value="12.4" spread="8.89"/>
                    <measurement group_id="B4" value="12.4" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Illness Therapy-Fatigue (FACIT-F) Scale</title>
          <description>The FACIT-F Scale is a 13-item questionnaire that assesses self-reported fatigue during the past 7 days and its impact upon daily activities and function. Scores range from 0 - 100, with higher scores indicating a lesser degree of fatigue.</description>
          <population>participants with a Baseline assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="256"/>
                    <count group_id="B3" value="148"/>
                    <count group_id="B4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.8" spread="22.1"/>
                    <measurement group_id="B2" value="69.3" spread="23.1"/>
                    <measurement group_id="B3" value="67.4" spread="23.1"/>
                    <measurement group_id="B4" value="68.8" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Activation Measure (PAM-13) Questionnaire</title>
          <description>The PAM-13 item scale is a measure used to assess the patient knowledge, skill, and confidence for self-management. Scores range from 0 to 100. Higher scores indicate and higher level of knowledge, skill and confidence.</description>
          <population>participants with a Baseline assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                    <count group_id="B2" value="207"/>
                    <count group_id="B3" value="139"/>
                    <count group_id="B4" value="387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="11.8"/>
                    <measurement group_id="B2" value="64.3" spread="10.1"/>
                    <measurement group_id="B3" value="63.0" spread="9.49"/>
                    <measurement group_id="B4" value="63.8" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Work Productivity and Activity Impairment (WPAI): Total Work Productivity Impairment</title>
          <description>The WPAI Hepatitis C V2.0 is an HCV specific questionnaire used to measure work absenteeism, work presenteeism, and daily activity impairment. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity.
Total work productivity impairment indicates the percentage of overall work impairment due to health problems.</description>
          <population>participants with a Baseline assessment</population>
          <units>percentage of work productivity impairme</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="105"/>
                    <count group_id="B3" value="58"/>
                    <count group_id="B4" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.2" spread="17.9"/>
                    <measurement group_id="B2" value="19.1" spread="28.0"/>
                    <measurement group_id="B3" value="18.1" spread="23.3"/>
                    <measurement group_id="B4" value="18.2" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WPAI: Total Activity Impairment</title>
          <description>The WPAI Hepatitis C V2.0 is an HCV specific questionnaire used to measure work absenteeism, work presenteeism, and daily activity impairment. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity.
Total activity impairment indicates the percentage of general (non-work) activity impairment due to health problems.</description>
          <population>participants with a Baseline assessment</population>
          <units>percentage of activity impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="242"/>
                    <count group_id="B3" value="147"/>
                    <count group_id="B4" value="432"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.0" spread="25.8"/>
                    <measurement group_id="B2" value="25.9" spread="27.3"/>
                    <measurement group_id="B3" value="28.0" spread="28.9"/>
                    <measurement group_id="B4" value="26.3" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response (SVR12)</title>
        <description>SVR12 is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (&lt; 50 IU/mL) 12 weeks after the last actual dose of the ABBVIE REGIMEN.</description>
        <time_frame>12 weeks after the last dose of study drug (treatment period was 12 or 24 weeks)</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known) with sufficient follow-up data regarding SVR12.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1 or 4, receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label</description>
          </group>
          <group group_id="O2">
            <title>All Genotype 1 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1, receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1a Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC G1a (includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/G4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 4 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response (SVR12)</title>
          <description>SVR12 is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (&lt; 50 IU/mL) 12 weeks after the last actual dose of the ABBVIE REGIMEN.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known) with sufficient follow-up data regarding SVR12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="423"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="278"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="88.4"/>
                    <measurement group_id="O3" value="77.9"/>
                    <measurement group_id="O4" value="93.9"/>
                    <measurement group_id="O5" value="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virological Response at End of Treatment (EoTR)</title>
        <description>Virological response is defined as HCV RNA &lt; 50 IU/mL. End of Treatment (EoT) is defined as the last intake of ABBVIE REGIMEN or RBV.</description>
        <time_frame>EoT, (treatment period was 12 weeks or 24 weeks)</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known).</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1 or 4, receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label</description>
          </group>
          <group group_id="O2">
            <title>All Genotype 1 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1, receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1a Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC G1a (includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/G4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 4 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virological Response at End of Treatment (EoTR)</title>
          <description>Virological response is defined as HCV RNA &lt; 50 IU/mL. End of Treatment (EoT) is defined as the last intake of ABBVIE REGIMEN or RBV.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="423"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="278"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4"/>
                    <measurement group_id="O2" value="94.8"/>
                    <measurement group_id="O3" value="89.0"/>
                    <measurement group_id="O4" value="97.8"/>
                    <measurement group_id="O5" value="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With On-Treatment Virological Failure or Relapse</title>
        <description>The number of participants meeting the following SVR12 non-response categories:
On-treatment virological failure (breakthrough) defined &gt;= 1 documented HCV RNA &lt; 50 IU/mL followed by HCV RNA &gt;= 50 IU/mL during treatment or failure to suppress (each measured on-treatment HCV RNA value &gt;= 50 IU/mL)
Relapse defined as HCV RNA &lt; 50 IU/mL at EoT followed by HCV RNA &gt;= 50 IU/mL post-treatment in participants who completed treatment (&lt;= 7 days shortened).</description>
        <time_frame>Up to post-treatment Week 12 (treatment period was 12 or 24 weeks)</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known). Participants with non-response 12 weeks after EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1 or 4, receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>All Genotype 1 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1, receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1a Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC G1a (includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/G4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 4 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With On-Treatment Virological Failure or Relapse</title>
          <description>The number of participants meeting the following SVR12 non-response categories:
On-treatment virological failure (breakthrough) defined &gt;= 1 documented HCV RNA &lt; 50 IU/mL followed by HCV RNA &gt;= 50 IU/mL during treatment or failure to suppress (each measured on-treatment HCV RNA value &gt;= 50 IU/mL)
Relapse defined as HCV RNA &lt; 50 IU/mL at EoT followed by HCV RNA &gt;= 50 IU/mL post-treatment in participants who completed treatment (&lt;= 7 days shortened).</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known). Participants with non-response 12 weeks after EoT.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On-Treatment Virological Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rapid Virological Response at Week 4 (RVR4)</title>
        <description>RVR4 is defined as participants with HCV RNA &lt; 50 IU/mL at Week 4.</description>
        <time_frame>Week 4</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known).</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1 or 4, receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>All Genotype 1 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1, receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1a Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC G1a (includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/G4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 4 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rapid Virological Response at Week 4 (RVR4)</title>
          <description>RVR4 is defined as participants with HCV RNA &lt; 50 IU/mL at Week 4.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="423"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="278"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0"/>
                    <measurement group_id="O2" value="57.2"/>
                    <measurement group_id="O3" value="62.1"/>
                    <measurement group_id="O4" value="54.7"/>
                    <measurement group_id="O5" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virological Response 24 Weeks After EoT (SVR24)</title>
        <description>SVR24 is defined as HCV RNA &lt; 50 IU/mL 24 Weeks After EoT.</description>
        <time_frame>24 Weeks After EoT (treatment period was 12 or 24 weeks)</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known) with sufficient follow-up data regarding SVR24.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1 or 4, receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label</description>
          </group>
          <group group_id="O2">
            <title>All Genotype 1 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1, receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1a Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC G1a (includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/G4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 4 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virological Response 24 Weeks After EoT (SVR24)</title>
          <description>SVR24 is defined as HCV RNA &lt; 50 IU/mL 24 Weeks After EoT.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known) with sufficient follow-up data regarding SVR24.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="228"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0"/>
                    <measurement group_id="O2" value="95.4"/>
                    <measurement group_id="O3" value="92.8"/>
                    <measurement group_id="O4" value="96.5"/>
                    <measurement group_id="O5" value="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virological Response 48 Weeks After EoT (SVR48)</title>
        <description>SVR48 is defined as participants with HCV RNA &lt; 50 IU/mL 48 weeks after EoT.</description>
        <time_frame>48 Weeks After EoT (treatment period was 12 or 24 weeks)</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known) with sufficient follow-up data regarding SVR48.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC), genotype 1 or 4, receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) according to standard of care and in line with the current local label</description>
          </group>
          <group group_id="O2">
            <title>Genotype 1 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1, receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1a Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC G1a (includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/G4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 4 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virological Response 48 Weeks After EoT (SVR48)</title>
          <description>SVR48 is defined as participants with HCV RNA &lt; 50 IU/mL 48 weeks after EoT.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known) with sufficient follow-up data regarding SVR48.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="164"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7"/>
                    <measurement group_id="O2" value="93.2"/>
                    <measurement group_id="O3" value="89.0"/>
                    <measurement group_id="O4" value="95.1"/>
                    <measurement group_id="O5" value="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PRISM Over Time</title>
        <description>PRISM is a visual quantitative method to assess the perceived burden of suffering due to illness. The distance between the center of the &quot;self&quot; (yellow disk) and the illness disk (red disk) is called &quot;self-illness separation&quot; (SIS) and is measured in cm (range is 0 - 27). The smaller the distance, the higher the burden of suffering.</description>
        <time_frame>Baseline, 12 and 48 weeks after EoT (treatment period was 12 or 24 weeks)</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known). Participants with a measurement at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>2 DAA+RBV</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
          <group group_id="O2">
            <title>3DAA</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN)</description>
          </group>
          <group group_id="O3">
            <title>3DAA+RBV</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN) + RBV</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PRISM Over Time</title>
          <description>PRISM is a visual quantitative method to assess the perceived burden of suffering due to illness. The distance between the center of the &quot;self&quot; (yellow disk) and the illness disk (red disk) is called &quot;self-illness separation&quot; (SIS) and is measured in cm (range is 0 - 27). The smaller the distance, the higher the burden of suffering.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known). Participants with a measurement at given time point.</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Weeks EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="222"/>
                    <count group_id="O3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" lower_limit="2.67" upper_limit="8.15"/>
                    <measurement group_id="O2" value="7.05" lower_limit="6.04" upper_limit="8.05"/>
                    <measurement group_id="O3" value="5.31" lower_limit="3.91" upper_limit="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Weeks EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="7.16" upper_limit="13.2"/>
                    <measurement group_id="O2" value="10.1" lower_limit="8.93" upper_limit="11.2"/>
                    <measurement group_id="O3" value="10.3" lower_limit="8.75" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1110</p_value>
            <p_value_desc>Between group change comparison: overall. The dependent variable is the change of PRISM from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2704</p_value>
            <p_value_desc>Between group change comparison: 3DAA - 2DAA+RBV. The dependent variable is the change of PRISM from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>4.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9516</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 2DAA+RBV. The dependent variable is the change of PRISM from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.17</ci_lower_limit>
            <ci_upper_limit>2.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0489</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 3DAA. The dependent variable is the change of PRISM from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.46</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9785</p_value>
            <p_value_desc>Between group change comparison: overall. The dependent variable is the change of PRISM from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9379</p_value>
            <p_value_desc>Between group change comparison: 3DAA - 2DAA+RBV. The dependent variable is the change of PRISM from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.37</ci_lower_limit>
            <ci_upper_limit>3.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9678</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 2DAA+RBV. The dependent variable is the change of PRISM from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.33</ci_lower_limit>
            <ci_upper_limit>3.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8373</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 3DAA. The dependent variable is the change of PRISM from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.70</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12 vs Baseline across all participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>paired t-test of whether difference in means is 0</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.417</ci_lower_limit>
            <ci_upper_limit>7.320</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48 vs Baseline across all participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>paired t-test of whether difference in means is 0</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.936</ci_lower_limit>
            <ci_upper_limit>11.362</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 1 Comorbidity and/or Co-Infection</title>
        <time_frame>up to post-treatment Week 48 (treatment period was 12 or 24 weeks)</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known).</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC), genotype 1 or 4, receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 1 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1, receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1a Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC G1a (includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/G4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 4 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 1 Comorbidity and/or Co-Infection</title>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="423"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="278"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0"/>
                    <measurement group_id="O2" value="69.3"/>
                    <measurement group_id="O3" value="71.0"/>
                    <measurement group_id="O4" value="68.3"/>
                    <measurement group_id="O5" value="76.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Taking ≥ 1 Co-Medication</title>
        <time_frame>up to post-treatment Week 48 (treatment period was 12 or 24 weeks)</time_frame>
        <population>Safety Population: all enrolled participants who received at least one dose of the ABBVIE REGIMEN (the prescribed ABBVIE REGIMEN was known).</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir [ABBVIE REGIMEN]) plus RBV
3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir [ABBVIE REGIMEN])
3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
          <group group_id="O2">
            <title>2 DAA+RBV</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
          <group group_id="O3">
            <title>3DAA</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN)</description>
          </group>
          <group group_id="O4">
            <title>3DAA+RBV</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Taking ≥ 1 Co-Medication</title>
          <population>Safety Population: all enrolled participants who received at least one dose of the ABBVIE REGIMEN (the prescribed ABBVIE REGIMEN was known).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="266"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1"/>
                    <measurement group_id="O2" value="64.4"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Duration of of ABBVIE REGIMEN and RBV Taken</title>
        <description>Documented by participant interview and/or participant diary.</description>
        <time_frame>Up to Week 12 or Week 24</time_frame>
        <population>Safety Population: all enrolled participants who received at least one dose of the ABBVIE REGIMEN (the prescribed ABBVIE REGIMEN was known) and had an assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir [ABBVIE REGIMEN]) plus RBV
3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir [ABBVIE REGIMEN])
3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
          <group group_id="O2">
            <title>2 DAA+RBV</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
          <group group_id="O3">
            <title>3DAA</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN)</description>
          </group>
          <group group_id="O4">
            <title>3DAA+RBV</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Duration of of ABBVIE REGIMEN and RBV Taken</title>
          <description>Documented by participant interview and/or participant diary.</description>
          <population>Safety Population: all enrolled participants who received at least one dose of the ABBVIE REGIMEN (the prescribed ABBVIE REGIMEN was known) and had an assessment.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="265"/>
                <count group_id="O4" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ABBVIE REGIMEN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="468"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="265"/>
                    <count group_id="O4" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="11.7"/>
                    <measurement group_id="O2" value="84" spread="3.4"/>
                    <measurement group_id="O3" value="83" spread="9.7"/>
                    <measurement group_id="O4" value="84" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" spread="18.1"/>
                    <measurement group_id="O2" value="84" spread="3.4"/>
                    <measurement group_id="O4" value="81" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Planned Duration of ABBVIE REGIMEN and RBV Taken</title>
        <description>Planned duration of treatment was 12 or 24 weeks.</description>
        <time_frame>Up to Week 12 or Week 24</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known). Participants taking specified study drug with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1 or 4, receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>All Genotype 1 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1, receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) ± RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 1a Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC G1a (includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 1b Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/G4), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 4 Participants</title>
            <description>Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir – ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Planned Duration of ABBVIE REGIMEN and RBV Taken</title>
          <description>Planned duration of treatment was 12 or 24 weeks.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known). Participants taking specified study drug with non-missing data.</population>
          <units>percentage of planned treatment duration</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="421"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="277"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ABBVIE REGIMEN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="468"/>
                    <count group_id="O2" value="421"/>
                    <count group_id="O3" value="144"/>
                    <count group_id="O4" value="277"/>
                    <count group_id="O5" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" spread="9.74"/>
                    <measurement group_id="O2" value="98.6" spread="10.18"/>
                    <measurement group_id="O3" value="97.7" spread="12.94"/>
                    <measurement group_id="O4" value="99.1" spread="8.39"/>
                    <measurement group_id="O5" value="99.8" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="156"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" spread="17.55"/>
                    <measurement group_id="O2" value="94.1" spread="19.72"/>
                    <measurement group_id="O3" value="95.3" spread="17.68"/>
                    <measurement group_id="O4" value="83.5" spread="30.68"/>
                    <measurement group_id="O5" value="99.8" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FACIT-F Scale Over Time</title>
        <description>The FACIT-F Scale is a 13-item questionnaire that assesses self-reported fatigue during the past 7 days and its impact upon daily activities and function. Scores range from 0 - 100, with higher scores indicating a lesser degree of fatigue.</description>
        <time_frame>Baseline, EoT (treatment period was 12 or 24 weeks), 12 and 48 weeks after EoT</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known). Participants with a measurement at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>2 DAA+RBV</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
          <group group_id="O2">
            <title>3DAA</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN)</description>
          </group>
          <group group_id="O3">
            <title>3DAA+RBV</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FACIT-F Scale Over Time</title>
          <description>The FACIT-F Scale is a 13-item questionnaire that assesses self-reported fatigue during the past 7 days and its impact upon daily activities and function. Scores range from 0 - 100, with higher scores indicating a lesser degree of fatigue.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known). Participants with a measurement at given time point.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="213"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="213"/>
                    <count group_id="O3" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="-2.35" upper_limit="10.7"/>
                    <measurement group_id="O2" value="6.45" lower_limit="4.05" upper_limit="8.86"/>
                    <measurement group_id="O3" value="4.49" lower_limit="1.17" upper_limit="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="205"/>
                    <count group_id="O3" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="6.78" upper_limit="18.3"/>
                    <measurement group_id="O2" value="9.92" lower_limit="7.87" upper_limit="12.0"/>
                    <measurement group_id="O3" value="10.2" lower_limit="7.37" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Weeks EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="4.71" upper_limit="22.0"/>
                    <measurement group_id="O2" value="9.68" lower_limit="6.87" upper_limit="12.5"/>
                    <measurement group_id="O3" value="10.3" lower_limit="6.37" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EOT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5751</p_value>
            <p_value_desc>Between group change comparison: overall. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5176</p_value>
            <p_value_desc>Between group change comparison: 3DAA - 2DAA+RBV. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>2.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.66</ci_lower_limit>
            <ci_upper_limit>9.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9308</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 2DAA+RBV. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>0.324</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.00</ci_lower_limit>
            <ci_upper_limit>7.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3462</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 3DAA. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-1.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.06</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 Weeks after EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7016</p_value>
            <p_value_desc>Between group change comparison: overall. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 weeks after EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4002</p_value>
            <p_value_desc>Between group change comparison: 3DAA - 2DAA+RBV. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-2.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.71</ci_lower_limit>
            <ci_upper_limit>3.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 weeks after EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4750</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 2DAA+RBV. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-2.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.74</ci_lower_limit>
            <ci_upper_limit>4.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 weeks after EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8740</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 3DAA. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>0.282</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.21</ci_lower_limit>
            <ci_upper_limit>3.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 weeks after EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7211</p_value>
            <p_value_desc>Between group change comparison: overall. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 weeks after EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4256</p_value>
            <p_value_desc>Between group change comparison: 3DAA - 2DAA+RBV. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-3.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.7</ci_lower_limit>
            <ci_upper_limit>5.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 weeks after EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5347</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 2DAA+RBV. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-3.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.6</ci_lower_limit>
            <ci_upper_limit>6.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 weeks after EoT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7920</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 3DAA. The dependent variable in the change of FACIT-F [0-100] from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>0.654</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.23</ci_lower_limit>
            <ci_upper_limit>5.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline to EOT across all participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>paired t-test of mean difference from 0</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.355</ci_lower_limit>
            <ci_upper_limit>7.935</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline vs 12 weeks after EOT across all participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>paired t-test of mean difference versus 0</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.113</ci_lower_limit>
            <ci_upper_limit>12.299</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>baseline vs 48 weeks after EOT across all participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>paired t-test of mean difference versus 0</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.259</ci_lower_limit>
            <ci_upper_limit>12.992</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to EoT in PAM-13 Questionnaire</title>
        <description>The PAM-13 item scale is a measure used to assess the patient knowledge, skill, and confidence for self-management. Scores range from 0 to 100. Higher scores indicate a higher level of knowledge, skill and confidence.</description>
        <time_frame>Baseline, EoT (treatment period was 12 or 24 weeks)</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known). Participants with a measurement at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>2 DAA+RBV</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
          <group group_id="O2">
            <title>3DAA</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN)</description>
          </group>
          <group group_id="O3">
            <title>3DAA+RBV</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in PAM-13 Questionnaire</title>
          <description>The PAM-13 item scale is a measure used to assess the patient knowledge, skill, and confidence for self-management. Scores range from 0 to 100. Higher scores indicate a higher level of knowledge, skill and confidence.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype; the prescribed ABBVIE REGIMEN was known). Participants with a measurement at given time point.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" lower_limit="-1.52" upper_limit="5.33"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-1.33" upper_limit="1.36"/>
                    <measurement group_id="O3" value="-0.74" lower_limit="-2.45" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3869</p_value>
            <p_value_desc>Between group change comparison: overall. The dependent variable in the change of PAM-13 from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3125</p_value>
            <p_value_desc>Between group change comparison: 3DAA - 2DAA+RBV. The dependent variable in the change of PAM-13 from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.57</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1741</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 2DAA+RBV. The dependent variable in the change of PAM-13 from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-2.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.48</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4941</p_value>
            <p_value_desc>Between group change comparison: 3DAA+RBV - 3DAA. The dependent variable in the change of PAM-13 from Baseline (Visit-Baseline). The analysis is adjusted for Baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.94</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline to Final visit across all participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8842</p_value>
            <method>paired t-test</method>
            <method_desc>paired t-test of mean difference vs 0</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.271</ci_lower_limit>
            <ci_upper_limit>1.096</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Over Time in WPAI: Total Work Productivity Impairment</title>
        <description>The WPAI Hepatitis C V2.0 is an HCV specific questionnaire used to measure work absenteeism, work presenteeism, and daily activity impairment. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity.
Total work productivity impairment indicates the percentage of overall work impairment due to health problems.</description>
        <time_frame>Baseline, EoT (treatment period was 12 or 24 weeks),12 and 24 weeks after EoT</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (the prescribed ABBVIE REGIMEN was known). Overall: participants with a measurement at Baseline; data rows = participants with a measurement at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV or 3DAA: paritaprevir/ritonavir - ombitasvir + dasabuvir [ABBVIE REGIMEN]) or 3DAA: paritaprevir/ritonavir - ombitasvir + dasabuvir (ABBVIE REGIMEN) + RBV</description>
          </group>
          <group group_id="O2">
            <title>2 DAA+RBV</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
          <group group_id="O3">
            <title>3DAA</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN)</description>
          </group>
          <group group_id="O4">
            <title>3DAA+RBV</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Over Time in WPAI: Total Work Productivity Impairment</title>
          <description>The WPAI Hepatitis C V2.0 is an HCV specific questionnaire used to measure work absenteeism, work presenteeism, and daily activity impairment. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity.
Total work productivity impairment indicates the percentage of overall work impairment due to health problems.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (the prescribed ABBVIE REGIMEN was known). Overall: participants with a measurement at Baseline; data rows = participants with a measurement at Baseline and given time point.</population>
          <units>percentage of overall work impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="31.4"/>
                    <measurement group_id="O2" value="5.0" spread="36.4"/>
                    <measurement group_id="O3" value="4.4" spread="27.1"/>
                    <measurement group_id="O4" value="7.5" spread="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="23.4"/>
                    <measurement group_id="O2" value="-4.2" spread="11.9"/>
                    <measurement group_id="O3" value="-3.8" spread="21.5"/>
                    <measurement group_id="O4" value="-5.4" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Weeks EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="22.1"/>
                    <measurement group_id="O2" value="-3.2" spread="33.6"/>
                    <measurement group_id="O3" value="-7.2" spread="22.1"/>
                    <measurement group_id="O4" value="-9.7" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Over Time in WPAI: Total Activity Impairment</title>
        <description>The WPAI Hepatitis C V2.0 is an HCV specific questionnaire used to measure work absenteeism, work presenteeism, and daily activity impairment. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity.
Total activity impairment indicates the percentage of general (non-work) activity impairment due to health problems.</description>
        <time_frame>Baseline, EoT (treatment period was 12 or 24 weeks),12 and 24 weeks after EoT</time_frame>
        <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (the prescribed ABBVIE REGIMEN was known). Overall: participants with a measurement at Baseline; data rows = participants with a measurement at Baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV or 3DAA: paritaprevir/ritonavir - ombitasvir + dasabuvir [ABBVIE REGIMEN]) or 3DAA: paritaprevir/ritonavir - ombitasvir + dasabuvir (ABBVIE REGIMEN) + RBV</description>
          </group>
          <group group_id="O2">
            <title>2 DAA+RBV</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
          <group group_id="O3">
            <title>3DAA</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN)</description>
          </group>
          <group group_id="O4">
            <title>3DAA+RBV</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Over Time in WPAI: Total Activity Impairment</title>
          <description>The WPAI Hepatitis C V2.0 is an HCV specific questionnaire used to measure work absenteeism, work presenteeism, and daily activity impairment. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity.
Total activity impairment indicates the percentage of general (non-work) activity impairment due to health problems.</description>
          <population>Core Population: Participants who were adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (the prescribed ABBVIE REGIMEN was known). Overall: participants with a measurement at Baseline; data rows = participants with a measurement at Baseline and given time point.</population>
          <units>percentage impairment of activity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="322"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="30.9"/>
                    <measurement group_id="O2" value="7.0" spread="25.2"/>
                    <measurement group_id="O3" value="-3.0" spread="28.9"/>
                    <measurement group_id="O4" value="-2.8" spread="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="189"/>
                    <count group_id="O4" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="27.0"/>
                    <measurement group_id="O2" value="-7.7" spread="22.0"/>
                    <measurement group_id="O3" value="-13.3" spread="24.8"/>
                    <measurement group_id="O4" value="-10.5" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Weeks EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="170"/>
                    <count group_id="O4" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="25.9"/>
                    <measurement group_id="O2" value="-11.3" spread="22.8"/>
                    <measurement group_id="O3" value="-12.3" spread="24.0"/>
                    <measurement group_id="O4" value="-16.3" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and/or Pregnancies</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence. If an AE meets any of the following criteria, it is considered serious: results in death, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in significant disability/incapacity, or is an important medical event. TEAEs are defined as any reported event that begins or worsens in severity after initiation of study drug through 30 days post-study drug dosing.</description>
        <time_frame>up to 30 days post treatment (treatment period was 12 weeks or 24 weeks)</time_frame>
        <population>Safety Population: all enrolled participants who received at least one dose of the ABBVIE REGIMEN (the prescribed ABBVIE REGIMEN was known). Pregnancy data presented for female participants only.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV or 3DAA: paritaprevir/ritonavir - ombitasvir + dasabuvir [ABBVIE REGIMEN]) or 3DAA: paritaprevir/ritonavir - ombitasvir + dasabuvir (ABBVIE REGIMEN) + RBV</description>
          </group>
          <group group_id="O2">
            <title>2 DAA+RBV</title>
            <description>Two direct-acting antivirals (2DAA): paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV</description>
          </group>
          <group group_id="O3">
            <title>3DAA</title>
            <description>Three direct-acting antivirals (3DAA): paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN)</description>
          </group>
          <group group_id="O4">
            <title>3DAA+RBV</title>
            <description>3DAA: paritaprevir/ritonavir – ombitasvir + dasabuvir (ABBVIE REGIMEN) + RBV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and/or Pregnancies</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence. If an AE meets any of the following criteria, it is considered serious: results in death, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in significant disability/incapacity, or is an important medical event. TEAEs are defined as any reported event that begins or worsens in severity after initiation of study drug through 30 days post-study drug dosing.</description>
          <population>Safety Population: all enrolled participants who received at least one dose of the ABBVIE REGIMEN (the prescribed ABBVIE REGIMEN was known). Pregnancy data presented for female participants only.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="266"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 1 TEAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="470"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="266"/>
                    <count group_id="O4" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Serious TEAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="470"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="266"/>
                    <count group_id="O4" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pregnancy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="124"/>
                    <count group_id="O4" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 30 days post treatment (treatment period was 12 weeks or 24 weeks)</time_frame>
      <desc>Treatment-emergent AEs are presented. Treatment-emergent AEs are defined as any reported AE that begins or worsens in severity after initiation of study drug through 30 days after last study drug intake.
Treatment duration was not a factor for assignment to reporting groups.</desc>
      <group_list>
        <group group_id="E1">
          <title>2 DAA+RBV</title>
          <description>2DAA: paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) plus RBV</description>
        </group>
        <group group_id="E2">
          <title>3DAA</title>
          <description>3DAA: paritaprevir/ritonavir - ombitasvir + dasabuvir (ABBVIE REGIMEN)</description>
        </group>
        <group group_id="E3">
          <title>3DAA+RBV</title>
          <description>3DAA: paritaprevir/ritonavir - ombitasvir + dasabuvir (ABBVIE REGIMEN) plus RBV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTRIC PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>OROPHARYNGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PSEUDARTHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="266"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="266"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

